Enliven Therapeutics ELVN
Ownership & positioning
Who holds it, who is betting against it, and where the big money is moving
Short-sale volume as % of daily volume
Large-order net flow, last 20 sessions
Net of large-order buying minus selling, in USD. Over this window: −$10.46M (8 inflow days, 12 outflow days).
Net flow by order size, last 20 sessions
Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.
The five largest holders on file together own 45.2% of shares outstanding.
Largest holders
By investor type
Reported short interest has risen from 11.27% to 14.05% of float over the last 6 biweekly reports (14 Aug 2026 to 30 Oct 2026).
Recent institutional activity
| Holder | Type | Period | Share change | New stake |
|---|---|---|---|---|
| Assenagon Asset Management S.A. | Mutual Fund | 2026/Q3 | +847,399 | 1.6% |
| BlackRock | Mutual Fund | 2026/Q3 | +846,877 | 7.1% |
| FMR | Mutual Fund | 2026/Q3 | +802,714 | 14.7% |
| Westfield Capital Management Company, L.P. | Mutual Fund | 2026/Q3 | +766,555 | 1.0% |
| State Street Global Advisors | Mutual Fund | 2026/Q3 | +333,150 | 2.1% |
| Principal Global Investors, LLC | Mutual Fund | 2026/Q3 | +332,238 | 0.5% |
| Vanguard Capital Management, LLC | Mutual Fund | 2026/Q3 | +324,107 | 3.9% |
| Geode Capital Management, LLC | Mutual Fund | 2026/Q3 | +301,718 | 2.3% |
| FMR | Mutual Fund | 2026/Q3 | +3,195,768 | 13.7% |
| T. Rowe Price Group, Inc. | Mutual Fund | 2026/Q3 | +3,107,051 | 4.4% |
| Norges Bank Investment Management | Sovereign Wealth Fund | 2026/Q3 | +1,382,333 | 1.9% |
| Polar Capital Holdings Plc | Mutual Fund | 2026/Q3 | +1,364,703 | 8.7% |
| First Light Asset Management, LLC | Mutual Fund | 2026/Q3 | +1,158,883 | 1.8% |
| Adage Capital Management, L.P. | Hedge Fund | 2026/Q3 | +1,083,313 | 1.5% |
| Artal Group S.A. | VC/PE Fund | 2026/Q3 | +1,028,185 | 2.4% |
Institutional buy/sell activity by reporting period, largest moves first.
Insider transactions
| Date | Insider | Title | Transaction | Shares | Price | Held after |
|---|---|---|---|---|---|---|
| 29 Oct 2026 | Lori Kunkel | Independent Director | Derivative Exercise and Retained | +11,041 | $18.30 | 52,925 |
| 18 Oct 2026 | Helen Collins | Chief Medical Officer | Derivative Exercise and Sale | -5,000 | $38.47 | 25,000 |
| 18 Oct 2026 | Benjamin Hohl | CFO & Head of Corporate Development | Derivative Exercise and Sale | -6,018 | $38.48 | 13,000 |
| 13 Oct 2026 | Kristine Ball | Director | Other Derivative Acquisition | +23,394 | $39.28 | 23,394 |
| 30 Sep 2026 | Scott Garland | Director | Derivative Exercise and Sale | -13,000 | $46.67 | – |
| 16 Sep 2026 | Helen Collins | Chief Medical Officer | Derivative Exercise and Sale | -5,000 | $51.48 | 25,000 |
| 16 Sep 2026 | Benjamin Hohl | CFO & Head of Corporate Development | Open Market Disposition | -2,036 | $51.49 | 13,000 |
| 16 Sep 2026 | Benjamin Hohl | CFO & Head of Corporate Development | Derivative Exercise and Sale | -3,982 | $50.72 | 13,000 |
| 3 Sep 2026 | Richard Heyman | Former Independent Chairperson | Intent to Sell (Form 144) | -38,000 | $59.29 | – |
| 16 Aug 2026 | Helen Collins | Chief Medical Officer | Derivative Exercise and Sale | -5,000 | $59.35 | 25,000 |
| 16 Aug 2026 | Benjamin Hohl | CFO & Head of Corporate Development | Automatic Disposition | -6,018 | $59.35 | 15,036 |
| 3 Aug 2026 | Mika Derynck | Independent Director | Derivative Exercise and Sale | -158,795 | $60.21 | – |
| 16 Jul 2026 | Helen Collins | Chief Medical Officer | Derivative Exercise and Sale | -5,000 | $53.92 | 25,000 |
| 16 Jul 2026 | Benjamin Hohl | CFO & Head of Corporate Development | Automatic Disposition | -4,946 | $53.87 | 21,054 |
| 16 Jul 2026 | Benjamin Hohl | CFO & Head of Corporate Development | Derivative Exercise and Sale | -1,072 | $52.32 | 21,054 |
| 5 Jul 2026 | Lori Kunkel | Independent Director | Automatic Disposition | -10,000 | $50.84 | 41,884 |
| 21 Jun 2026 | OrbiMed Advisors LLC | Private Disposition | -48,253 | $45.00 | 6,774,507 | |
| 21 Jun 2026 | OrbiMed Advisors LLC | Open Market Disposition | -811,870 | $45.38 | 6,774,507 | |
| 16 Jun 2026 | Helen Collins | Chief Medical Officer | Derivative Exercise and Sale | -5,000 | $44.74 | 25,000 |
| 16 Jun 2026 | Benjamin Hohl | CFO & Head of Corporate Development | Derivative Exercise and Sale | -6,018 | $44.75 | 26,000 |
From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.
Short interest, by report
| Report date | Shares short | % of float | Days to cover |
|---|---|---|---|
| 30 Oct 2026 | 10,293,807 | 14.0% | 5.7 |
| 15 Oct 2026 | 9,331,398 | 12.7% | 7.5 |
| 30 Sep 2026 | 10,356,282 | 14.1% | 5.5 |
| 15 Sep 2026 | 8,620,503 | 11.8% | 9.0 |
| 31 Aug 2026 | 8,600,289 | 11.7% | 11.1 |
| 14 Aug 2026 | 8,258,991 | 11.3% | 6.3 |
No comments yet — be the first to weigh in on ELVN.
Sign in to join the discussion.